These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 33737337)

  • 41. [Mechanisms of resistance and escape to CAR-T cells].
    Grinda T; Brouard J; Tran D; Rubio MT
    Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.
    Peng L; Sferruzza G; Yang L; Zhou L; Chen S
    Cell Mol Immunol; 2024 Oct; 21(10):1089-1108. PubMed ID: 39134804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.
    Cordeau M; Belounis A; Lelaidier M; Cordeiro P; Sartelet H; Herblot S; Duval M
    PLoS One; 2016; 11(10):e0164401. PubMed ID: 27716850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.
    Rivera Z; Escutia C; Madonna MB; Gupta KH
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
    Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
    Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
    Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.
    Spel L; Boelens JJ; van der Steen DM; Blokland NJ; van Noesel MM; Molenaar JJ; Heemskerk MH; Boes M; Nierkens S
    Oncotarget; 2015 Nov; 6(34):35770-81. PubMed ID: 26452036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma.
    Sha YL; Liu Y; Yang JX; Wang YY; Gong BC; Jin Y; Qu TY; Xia FT; Han L; Zhao Q
    J Exp Clin Cancer Res; 2022 Oct; 41(1):314. PubMed ID: 36284313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
    Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an
    Orienti I; Farruggia G; Nguyen F; Guan P; Calonghi N; Kolla V; Chorny M; Brodeur GM
    Int J Nanomedicine; 2020; 15():6873-6886. PubMed ID: 32982239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
    Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
    Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.